Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Dec 2024 value amounting to $17.7 million.

  • Mirum Pharmaceuticals' Cash from Financing Activities rose 316.67% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.5 million, marking a year-over-year increase of 158.09%. This contributed to the annual value of $17.7 million for FY2024, which is 94.74% down from last year.
  • Mirum Pharmaceuticals' Cash from Financing Activities amounted to $17.7 million in FY2024, which was down 94.74% from $336.6 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash from Financing Activities peaked at $336.6 million during FY2023, and registered a low of $17.7 million during FY2024.
  • Moreover, its 3-year median value for Cash from Financing Activities was $109.1 million (2022), whereas its average is $154.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first spiked by 208.56% in 2023, then slumped by 94.74% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $181.3 million in 2020, then slumped by 59.48% to $73.5 million in 2021, then surged by 48.49% to $109.1 million in 2022, then spiked by 208.56% to $336.6 million in 2023, then crashed by 94.74% to $17.7 million in 2024.